Overview

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Status:
Completed
Trial end date:
2019-04-12
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD9150 monotherapy and AZD9150 in combination with durvalumab in Japanese patients with advanced solid malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Durvalumab